Skip to content

ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY (AMPORA)

Post-Operative Prostate Cancer

This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.

null

Conditions de participation

  • Sexe:

    MALE

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

1. Age \> 18 years
2. Able to provide informed consent
3. Histologic diagnosis of prostate adenocarcinoma
4. ECOG performance status 0-1
5. Previous radical prostatectomy \> 6 months prior to radiotherapy start date
6. Planned to receive post-operative radiation

Exclusion Criteria:

1. Prior pelvic radiotherapy
2. Contraindications to radiotherapy
3. Mets confirmed as per (if scan has been done for clinical care)
4. Participants with visible disease in the prostate bed or pelvic lymph nodes on imaging are not eligible for treatment on study.

Lieu de l'étude

University Health Network - Princess Margaret Cancer Centre
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Andrew McPartlin

[email protected]
416-946-4501
Étude parrainée par
University Health Network, Toronto
Participants recherchés
Plus d'informations
ID de l'étude: NCT06409910